Enterprise Value
1.085B
Cash
148.2M
Avg Qtr Burn
N/A
Short % of Float
11.29%
Insider Ownership
5.95%
Institutional Own.
82.72%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
FYCOMPA Details Epilepsy | Approved Quarterly sales | |
FIRDAPSE®(Amifampridine) Details Autoimmune disease, Lamber-Eaton myasthenic syndrome | Approved Quarterly sales | |
FIRDAPSE® (Amifampridine) Details Autoimmune disease, Neuromuscular disease | Failed Discontinued |